The mean CPK level before starting PCSK9 inhibitor therapy was 1028.6 ± 749.43 IU/L, while the most recent measurement after myositis treatment and the use of PCSK9 inhibitors was within normal limits (135 IU/L). The gene discussed is PIK3C2A; the disease is myositis disease.